Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
32 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2016', provides an overview of the Fibrinogen Deficiency (Factor I Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Fibrinogen Deficiency (Factor I Deficiency) - The report reviews pipeline therapeutics for Fibrinogen Deficiency (Factor I Deficiency) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Fibrinogen Deficiency (Factor I Deficiency) therapeutics and enlists all their major and minor projects - The report assesses Fibrinogen Deficiency (Factor I Deficiency) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Fibrinogen Deficiency (Factor I Deficiency) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Fibrinogen Deficiency (Factor I Deficiency) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Fibrinogen Deficiency (Factor I Deficiency) Overview 6 Therapeutics Development 7 Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) - Overview 7 Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics under Development by Companies 8 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Fibrinogen Deficiency (Factor I Deficiency) - Products under Development by Companies 11 Fibrinogen Deficiency (Factor I Deficiency) - Companies Involved in Therapeutics Development 12 Biotest AG 12 China Biologic Products, Inc. 13 Grifols, S.A. 14 LFB S.A. 15 Octapharma AG 16 Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Drug Profiles 23 fibrinogen (human) - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 fibrinogen concentrate (human) - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 fibrinogen concentrate (human) - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 fibrinogen concentrate (human) - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 fibrinogen concentrate (human) - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Fibrinogen Deficiency (Factor I Deficiency) - Dormant Projects 28 Fibrinogen Deficiency (Factor I Deficiency) - Discontinued Products 29 Fibrinogen Deficiency (Factor I Deficiency) - Product Development Milestones 30 Featured News & Press Releases 30 Mar 23, 2012: China Biologic Receives SFDA Approval To Begin Clinical Trials For Human Fibrinogen 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 31 Disclaimer 32
List of Tables
Number of Products under Development for Fibrinogen Deficiency (Factor I Deficiency), H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Products under Development by Companies, H2 2016 11 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Biotest AG, H2 2016 12 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by China Biologic Products, Inc., H2 2016 13 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Grifols, S.A., H2 2016 14 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by LFB S.A., H2 2016 15 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Octapharma AG, H2 2016 16 Assessment by Monotherapy Products, H2 2016 17 Number of Products by Stage and Target, H2 2016 18 Number of Products by Stage and Mechanism of Action, H2 2016 19 Number of Products by Stage and Route of Administration, H2 2016 21 Number of Products by Stage and Molecule Type, H2 2016 22 Fibrinogen Deficiency (Factor I Deficiency) - Dormant Projects, H2 2016 28 Fibrinogen Deficiency (Factor I Deficiency) - Discontinued Products, H2 2016 29
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
